https://www.cancernetwork.com/view/practice-changes-key-takeaways-and-closing-remarks2026-09-30T17:56:59.509Z2026-09-30T17:56:59.509Z https://www.cancernetwork.com/view/triaging-post-car-t-complications-in-two-practical-scenarios2026-09-30T17:56:58.308Z2026-09-30T17:56:58.308Z https://www.cancernetwork.com/view/recognizing-delayed-neurotoxicity-and-immune-effector-cell-enterocolitis2026-09-30T17:56:56.827Z2026-09-30T17:56:56.827Z https://www.cancernetwork.com/view/long-term-monitoring-prophylaxis-and-vaccination-after-cilta-cel2026-09-30T17:56:55.378Z2026-09-30T17:56:55.378Z https://www.cancernetwork.com/view/day-28-discharge-and-transition-to-shared-community-care2026-09-30T17:56:53.731Z2026-09-30T17:56:53.731Z https://www.cancernetwork.com/view/timing-referral-holding-therapy-and-bridging-therapy-definitions2026-09-30T17:56:52.048Z2026-09-30T17:56:52.048Z https://www.cancernetwork.com/view/building-referral-relationships-with-community-oncology-practices2026-09-30T17:56:50.609Z2026-09-30T17:56:50.609Z https://www.cancernetwork.com/view/ciltacabtagene-autoleucel-manufacturing-debulking-and-bridging-in-multiple-myeloma2026-09-30T17:56:49.143Z2026-09-30T17:56:49.143Z https://www.cancernetwork.com/view/referral-barriers-to-chimeric-antigen-receptor-t-cell-therapy-in-multiple-myeloma2026-09-30T17:56:47.131Z2026-09-30T17:56:47.131Z https://www.cancernetwork.com/view/excaliber-rrmm-iberdomide-in-relapsed-refractory-multiple-myeloma2026-09-30T16:05:00Z2026-09-30T16:05:00Z https://www.cancernetwork.com/view/follow-up-after-a-one-time-therapy-and-shared-care-with-community-practices2026-09-30T16:00:00Z2026-09-30T16:00:00Z https://www.cancernetwork.com/view/aglatimagene-combo-shows-sustained-immune-remodeling-in-prostate-cancer2026-09-30T16:00:00Z2026-09-30T16:00:00Z https://www.cancernetwork.com/view/introduction-to-celmods-in-relapsed-refractory-multiple-myeloma2026-09-30T16:00:00Z2026-09-30T16:00:00Z https://www.cancernetwork.com/view/cartitude-2-cohort-a-follow-up-data-and-preparing-patients-for-car-tcell-therapy2026-09-30T15:54:00Z2026-09-30T15:54:00Z https://www.cancernetwork.com/view/tile-based-radiation-improves-surgical-bed-recurrence-in-brain-metastases2026-09-30T15:00:00Z2026-09-30T15:00:00Z https://www.cancernetwork.com/view/sbrt-matches-chemoradiation-preserves-qol-before-pancreatic-surgery2026-09-30T14:00:00Z2026-09-30T14:00:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-the-comorbid-higher-risk-patient-and-program-conclusions2026-09-30T12:55:00Z2026-09-30T12:55:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-the-fit-immunotherapy-eligible-patient-in-second-line2026-09-30T12:50:00Z2026-09-30T12:50:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-case-based-discussion-rapidly-progressive-earlier-relapse-disease2026-09-30T12:45:00Z2026-09-30T12:45:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-debate-contextualizing-safety-and-sequencing-bcma-directed-therapies2026-09-30T12:40:00Z2026-09-30T12:40:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-debate-treatment-selection-between-car-t-cell-and-bispecific-approaches-in-second-line-disease2026-09-30T12:35:00Z2026-09-30T12:35:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-safety-and-real-world-management-of-bcma-directed-therapies2026-09-30T12:30:00Z2026-09-30T12:30:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-cartitude-4-long-term-outcomes-and-treatment-free-remission-with-cilta-cel2026-09-30T12:25:00Z2026-09-30T12:25:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-majestec-9-and-teclistamab-monotherapy-in-lenalidomide-and-anti-cd38-double-refractory-disease2026-09-30T12:20:00Z2026-09-30T12:20:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-real-world-treatment-patterns-attrition-and-the-case-for-earlier-bcma-directed-therapy2026-09-30T12:15:00Z2026-09-30T12:15:00Z https://www.cancernetwork.com/view/relapsed-refractory-multiple-myeloma-majestec-3-and-the-bispecific-antibody-approach-in-earlier-relapse-disease2026-09-30T12:10:00Z2026-09-30T12:10:00Z https://www.cancernetwork.com/view/shared-decision-making-in-relapsed-refractory-multiple-myeloma2026-09-30T12:05:00Z2026-09-30T12:05:00Z https://www.cancernetwork.com/view/copernicus-design-prophylaxis-counseling-and-brain-metastases2026-09-30T12:05:00Z2026-09-30T12:05:00Z https://www.cancernetwork.com/view/dreamm-7-design-efficacy-and-safety2026-09-30T12:05:00Z2026-09-30T12:05:00Z https://www.cancernetwork.com/view/molecular-testing-turnaround-time-and-response-assessment2026-09-30T12:05:00Z2026-09-30T12:05:00Z https://www.cancernetwork.com/view/evolving-treatment-goals-in-multiple-myeloma2026-09-30T12:05:00Z2026-09-30T12:05:00Z https://www.cancernetwork.com/view/menin-inhibitor-landscape-in-npm1-mutated-and-kmt2a-rearranged-aml2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/evolution-of-frontline-therapy-in-multiple-myeloma2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/self-advocacy-and-treatment-decisions-in-relapsed-refractory-multiple-myeloma2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/extended-anticoagulation-and-skin-care-adherence-on-amivantamab2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/sequencing-fgfr2-inhibitors-in-previously-treated-cholangiocarcinoma2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/patient-selection-for-belantamab-mafodotin2026-09-30T12:00:00Z2026-09-30T12:00:00Z https://www.cancernetwork.com/view/integrating-talazoparib-plus-enzalutamide-into-hrr-mutated-mhspc-care2026-09-29T22:00:00Z2026-09-29T22:00:00Z https://www.cancernetwork.com/view/lirafugratinib-approval-adds-a-third-fgfr2-inhibitor-in-cholangiocarcinoma2026-09-29T21:00:00Z2026-09-29T21:00:00Z https://www.cancernetwork.com/view/srs-improves-survival-vs-hippocampal-avoidant-wbrt-in-sclc-brain-metastases2026-09-29T20:00:00Z2026-09-29T20:00:00Z https://www.cancernetwork.com/view/bcma-gprc5d-car-t-cell-therapy-shows-early-efficacy-in-r-r-multiple-myeloma2026-09-29T19:00:00Z2026-09-29T19:00:00Z https://www.cancernetwork.com/view/when-single-fraction-srs-still-makes-sense-for-resected-brain-metastases2026-09-29T18:00:00Z2026-09-29T18:00:00Z https://www.cancernetwork.com/view/extended-belantamab-mafodotin-dosing-eases-ocular-function-in-dreamm-92026-09-29T17:00:00Z2026-09-29T17:00:00Z https://www.cancernetwork.com/view/proton-therapy-does-not-improve-survival-in-hepatocellular-carcinoma2026-09-29T16:00:07.919Z2026-09-29T16:00:07.919Z https://www.cancernetwork.com/view/multimodal-biopsy-combo-shows-low-morbidity-in-suspected-prostate-cancer2026-09-29T15:00:00Z2026-09-29T15:00:00Z https://www.cancernetwork.com/view/where-mrd-testing-fits-into-myeloma-s-treatment-and-regulatory-landscape2026-09-29T14:00:00Z2026-09-29T14:00:00Z https://www.cancernetwork.com/view/dreamm-7-study-design-and-the-rationale2026-09-29T12:05:00Z2026-09-29T12:05:00Z https://www.cancernetwork.com/view/proton-hypofractionated-radiation-shine-in-nonoperative-cholangiocarcinoma2026-09-29T12:00:00Z2026-09-29T12:00:00Z https://www.cancernetwork.com/view/from-accelerated-approval-to-reapproval-of-belantamab-mafodotin2026-09-29T12:00:00Z2026-09-29T12:00:00Z https://www.cancernetwork.com/view/hypofractionated-pmrt-shows-durable-10-year-control-in-high-risk-breast-cancer2026-09-28T22:30:00Z2026-09-28T22:30:00Z https://www.cancernetwork.com/view/fractionated-srs-tops-single-fraction-srs-after-brain-metastasis-resection2026-09-28T21:30:00Z2026-09-28T21:30:00Z https://www.cancernetwork.com/view/exploring-advancements-in-targeting-kras-in-cholangiocarcinoma2026-09-28T21:00:00Z2026-09-28T21:00:00Z https://www.cancernetwork.com/view/sequencing-car-t-therapy-and-bispecifics-in-follicular-and-mantle-cell-lymphoma2026-09-28T20:00:00Z2026-09-28T20:00:00Z https://www.cancernetwork.com/view/fractionated-srs-should-be-standard-of-care-after-brain-metastasis-surgery2026-09-28T19:30:00Z2026-09-28T19:30:00Z https://www.cancernetwork.com/view/first-in-human-jyoti-malhotra-md-mph-on-phase-i-trials-lung-cancer-in-2026-and-yale2026-09-28T19:00:00Z2026-09-28T19:00:00Z https://www.cancernetwork.com/view/ctdna-assay-shows-high-specificity-for-post-transplant-liver-cancer-recurrence2026-09-28T18:00:00Z2026-09-28T18:00:00Z https://www.cancernetwork.com/view/hydrogel-spacer-receives-fda-510-k-clearance-for-prostate-cancer-radiotherapy2026-09-28T17:00:00Z2026-09-28T17:00:00Z https://www.cancernetwork.com/view/evorpacept-plus-trp-improves-orr-in-pretreated-her2-gastric-cancer2026-09-28T16:30:00Z2026-09-28T16:30:00Z https://www.cancernetwork.com/view/pds0101-pembrolizumab-yields-39-3-month-median-os-in-hpv16-positive-hnscc2026-09-28T16:00:00Z2026-09-28T16:00:00Z https://www.cancernetwork.com/view/distal-extrahepatic-cholangiocarcinoma-may-gain-from-neoadjuvant-radiation2026-09-28T15:00:00Z2026-09-28T15:00:00Z https://www.cancernetwork.com/view/pirtobrutinib-earns-approval-in-china-for-cll-sll-across-all-therapy-lines2026-09-28T14:30:00Z2026-09-28T14:30:00Z https://www.cancernetwork.com/view/the-value-of-testing-in-the-expanding-egfr-exon-20-insertion-landscape2026-09-28T14:00:00Z2026-09-28T14:00:00Z https://www.cancernetwork.com/view/flaura2-survival-and-limits-of-cross-trial-comparison2026-09-28T12:05:00Z2026-09-28T12:05:00Z https://www.cancernetwork.com/view/choosing-between-regimens-future-directions-and-key-takeaways2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.cancernetwork.com/view/emerging-clinical-evidence-and-future-role-of-celmods-in-multiple-myeloma2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.cancernetwork.com/view/how-oncologists-can-navigate-patient-requests-for-medical-aid-in-dying2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.cancernetwork.com/view/weighing-toxicity-against-survival-benefit-in-counseling2026-09-28T12:00:00Z2026-09-28T12:00:00Z https://www.cancernetwork.com/view/neoadjuvant-radiation-may-improve-tolerability-in-cholangiocarcinoma2026-09-27T18:00:00Z2026-09-27T18:00:00Z https://www.cancernetwork.com/view/isatuximab-based-therapy-shows-impressive-pfs-projections-in-ndmm2026-09-27T17:00:00Z2026-09-27T17:00:00Z https://www.cancernetwork.com/view/how-are-personalized-frontline-multiple-myeloma-treatments-evolving-2026-09-27T17:00:00Z2026-09-27T17:00:00Z https://www.cancernetwork.com/view/applying-the-ims-imwg-definition-of-cure-in-community-myeloma-practice2026-09-27T16:00:00Z2026-09-27T16:00:00Z https://www.cancernetwork.com/view/subcutaneous-isatuximab-enhances-patient-experience-in-multiple-myeloma2026-09-27T15:00:00Z2026-09-27T15:00:00Z https://www.cancernetwork.com/view/iberdomide-triplet-improves-mrd-negative-crs-in-r-r-multiple-myeloma2026-09-26T20:00:00Z2026-09-26T20:00:00Z https://www.cancernetwork.com/view/how-academic-community-oncologists-improve-access-to-new-myeloma-therapies2026-09-26T19:00:00Z2026-09-26T19:00:00Z https://www.cancernetwork.com/view/managing-sustained-mrd-negativity-after-multiple-myeloma-therapy-ends2026-09-26T18:00:00Z2026-09-26T18:00:00Z https://www.cancernetwork.com/view/perseus-trial-shows-daratumumab-regimen-deepens-responses-in-ndmm2026-09-26T17:00:00Z2026-09-26T17:00:00Z https://www.cancernetwork.com/view/defining-the-role-of-neoadjuvant-radiation-in-cholangiocarcinoma2026-09-26T16:00:00Z2026-09-26T16:00:00Z https://www.cancernetwork.com/view/etentamig-shows-superior-efficacy-vs-soc-in-relapsed-refractory-myeloma2026-09-26T15:00:00Z2026-09-26T15:00:00Z https://www.cancernetwork.com/view/celmod-based-maintenance-deepens-responses-after-asct-in-multiple-myeloma2026-09-26T13:00:00Z2026-09-26T13:00:00Z https://www.cancernetwork.com/view/nursing-strategies-for-the-3-first-line-regimens-in-egfr-mutated-nsclc2026-09-25T21:00:00Z2026-09-25T21:00:00Z https://www.cancernetwork.com/view/how-can-literature-and-peer-review-impact-an-oncology-fellow-s-career-2026-09-25T19:00:00Z2026-09-25T19:00:00Z https://www.cancernetwork.com/view/targeted-agents-amyloidosis-and-defining-a-cure-in-plasma-cell-disorders2026-09-25T18:00:00Z2026-09-25T18:00:00Z https://www.cancernetwork.com/view/sustained-mrd-negativity-with-dvrd-signals-long-term-survival-in-ndmm2026-09-25T17:36:44.337Z2026-09-25T17:36:44.337Z https://www.cancernetwork.com/view/switching-to-sc-dosing-and-considering-pro-data-for-amivantamab-in-nsclc2026-09-25T17:00:00Z2026-09-25T17:00:00Z https://www.cancernetwork.com/view/durvalumab-plus-enfortumab-vedotin-earns-fda-priority-review-in-mibc2026-09-25T16:00:00Z2026-09-25T16:00:00Z https://www.cancernetwork.com/view/isatuximab-combo-increases-mrd-negativity-in-mrd-positive-multiple-myeloma2026-09-25T15:00:00Z2026-09-25T15:00:00Z https://www.cancernetwork.com/view/fda-clears-trinav-advance-for-expanded-liver-embolization-access2026-09-25T12:00:00Z2026-09-25T12:00:00Z https://www.cancernetwork.com/view/cevostamab-combo-shows-durable-responses-in-r-r-multiple-myeloma2026-09-24T21:00:00Z2026-09-24T21:00:00Z https://www.cancernetwork.com/view/belzutifan-combo-receives-fda-approval-in-advanced-clear-cell-rcc2026-09-24T19:29:02.502Z2026-09-24T19:29:02.502Z https://www.cancernetwork.com/view/melt-mm-regimen-yields-responses-in-relapsed-refractory-multiple-myeloma2026-09-24T19:00:00Z2026-09-24T19:00:00Z https://www.cancernetwork.com/view/soho-02-trial-will-confirm-sevabertinib-s-frontline-nsclc-benefit2026-09-24T18:00:00Z2026-09-24T18:00:00Z https://www.cancernetwork.com/view/daratumumab-combo-yields-responses-in-cardiac-involved-al-amyloidosis-trials2026-09-24T17:00:00Z2026-09-24T17:00:00Z https://www.cancernetwork.com/view/epcoritamab-combo-receives-canadian-approval-in-r-r-follicular-lymphoma2026-09-24T16:00:00Z2026-09-24T16:00:00Z https://www.cancernetwork.com/view/how-kras-g12c-data-should-shape-combination-trial-design2026-09-24T14:00:00Z2026-09-24T14:00:00Z https://www.cancernetwork.com/view/emerging-endocrine-doublets-and-serial-esr1-testing-in-hr-her2-mbc2026-09-24T12:05:00Z2026-09-24T12:05:00Z https://www.cancernetwork.com/view/the-case-for-frontline-zongertinib-in-her2-mutant-nsclc2026-09-24T12:05:00Z2026-09-24T12:05:00Z https://www.cancernetwork.com/view/anselamimab-s-kappa-subgroup-signal-could-reshape-anti-fibril-therapy-in-al-amyloidosis2026-09-24T12:00:00Z2026-09-24T12:00:00Z https://www.cancernetwork.com/view/acting-on-a-her2-result-and-navigating-access-to-therapy2026-09-24T12:00:00Z2026-09-24T12:00:00Z https://www.cancernetwork.com/view/patient-centered-treatment-transitions-in-hr-her2-mbc2026-09-24T12:00:00Z2026-09-24T12:00:00Z https://www.cancernetwork.com/view/fda-mcgp-panel-votes-in-favor-of-the-galleri-multicancer-early-detection-test2026-09-23T21:34:06.874Z2026-09-23T21:34:06.874Z